Dr. Bob A. Wise

Paul M. Hassoun, M.D., is professor of medicine at the Johns Hopkins University School of Medicine and the director of the pulmonary hypertension program at Johns Hopkins Hospital. He received his medical degree from the Faculté de Médecine Lariboisière-Saint Louis at the University of Paris, France, completed an internship and residency at Brigham and Women’s Hospital and a fellowship in Pulmonary and Critical Care Medicine at Massachusetts General Hospital, both at Harvard Medical School. He was on faculty in the pulmonary division at New England Medical Center/Tufts University School of Medicine (Tufts-NEMC) in Boston, MA, until 2002 when he joined the division of pulmonary and critical care medicine at Johns Hopkins University. Dr. Hassoun has served or currently serves on numerous American Thoracic Society (ATS) assemblies and committees, including the Pulmonary Circulation Long Range Planning Committee, the Pulmonary Circulation Program Committee (for which he served as chair for 2008-2009), the ATS Scientific Advisory Council, Pulmonary Circulation Leadership Committee, and the American College of Chest Physicians Vascular Steering Committee. He served as the ATS Pulmonary Circulation chair (2011-2012) and on the ATS Publications Policy Committee. He was recently elected president of the Pulmonary Vascular Research Institute (PVRI; 2018-2019). Dr. Hassoun has held numerous editorial activities including serving on the editorial board of the American Journal of Respiratory and Critical Medicine (2010 to present), CHEST (2006-2015) and the European Respiratory Review (2008-2015). He currently serves as associate editor of the European Respiratory Journal (2013-present) and has served as associate editor for the Journal of Clinical Investigation (2017-2022). Dr. Hassoun is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Systemic Sclerosis (SSc), Pulmonary Veno-Occlusive Disease, Cerebral Hypoxia, and Lung Transplant.

Matthew Lammi, MD MSCR is an Associate Professor of Medicine and part of the Interstitial Lung Disease (ILD) Program. Dr. Lammi obtained his medical degree from Temple University School of Medicine and did his internal medicine, pulmonary, and critical care training at Temple University Hospital. He then joined the faculty at LSU in New Orleans, where he served as the Director of the Comprehensive Pulmonary Hypertension Center. He joined Johns Hopkins in 2023. He currently serves as the Associate Director of the Johns Hopkins Pulmonary Fibrosis Foundation Care Center and is the Associate Program Director for the Advanced Lung Disease Fellowship. His research focuses on the intersection between ILD and pulmonary hypertension, particularly in patients with systemic sclerosis. He is currently a co-Principal Investigator for a clinical trial of therapy for scleroderma associated pulmonary hypertension supported by the Department of Defense Peer Reviewed Medical Research Program. He is active in numerous societies and serves as the Chair of the Research Committee for the Pulmonary Hypertension Association. Dr. Lammi is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Sarcoidosis, Systemic Sclerosis (SSc), Interstitial Lung Disease, and Lung Transplant.

Stephen C. Mathai, MD, MHS is an Associate Professor of Medicine and part of the Johns Hopkins Pulmonary Hypertension Program. Dr. Mathai received his undergraduate degree from Rutgers College and medical degree from Jefferson Medical College. He pursued residency training in Internal Medicine at Thomas Jefferson University Hospital, where he also served as Chief Medical Resident. Dr. Mathai came to Johns Hopkins for fellowship training in Pulmonary and Critical Care Medicine. During his 5-year fellowship, he obtained a Masters of Health Science degree from the Johns Hopkins Bloomberg School of Public Health and successfully competed for an individual Ruth L. Kirschstein National Research Service Award. Subsequently, he received a K23 award for his research in pulmonary vascular disease in scleroderma. He currently serves as Co-Principal Investigator for the Johns Hopkins PVDOMICS program supported by the NIH and is principal investigator for a clinical trial of therapy for scleroderma associated pulmonary hypertension supported by the Department of Defense Peer Reviewed Medical Research Program. He is also the Co-Director of the Ann Dana Kusch Multidisciplinary Program for Interstitial Lung Disease and Pulmonary Hypertension. Dr. Mathai has been active in numerous committees and holds several leadership positions in academic societies. He is the current chair of the Pulmonary Vascular Disease Network for the American College of Chest Physicians and has served on the steering committee for this organization for the past 4 years. He has served on several committees for the Pulmonary Circulation Assembly of the American Thoracic Society, including the Program Committee and Nominations Committee. He has organized symposia and delivered presentations related to pulmonary hypertension at numerous international meetings. He is the author of more than 100 publications and has given invited research lectures nationally and internationally. Dr. Mathai is also an active member of patient advocacy organizations. Currently, he is a member of the Scientific Leadership Council of the Pulmonary Hypertension Association where he serves as national chairperson of the Preceptorship Program Planning Committee. He is also a member of the Rare Disease Advisory Panel for the Patient Centered Outcomes Research Institute. Dr. Mathai also serves as the faculty leader of the inpatient pulmonary service, the Carol Johns Service, where he is responsible for the education of the internal medicine housestaff and pulmonary fellows. He has also received the Frederick L. Brancati Award for mentorship from the Department of Medicine at Johns Hopkins. Dr. Mathai is rated as a Distinguished provider by MediFind in the treatment of Systemic Sclerosis (SSc). His top areas of expertise are Pulmonary Hypertension, Systemic Sclerosis (SSc), Pulmonary Veno-Occlusive Disease, Sarcoidosis, and Lung Transplant.